{"id":46039,"date":"2025-11-07T11:40:24","date_gmt":"2025-11-07T03:40:24","guid":{"rendered":"https:\/\/flcube.com\/?p=46039"},"modified":"2025-11-07T11:40:25","modified_gmt":"2025-11-07T03:40:25","slug":"astrazeneca-posts-11-y-y-revenue-rise-to-43-24-bn-in-first-nine%e2%80%91months-of-2025","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46039","title":{"rendered":"AstraZeneca Posts 11% Y\/Y Revenue Rise to $43.24\u202fbn in First Nine\u2011Months of 2025"},"content":{"rendered":"\n<p>AstraZeneca (AZ, <a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NASDAQ\">NASDAQ: AZN<\/a>) released its third\u2011quarter and nine\u2011month 2025 financial results, showing <strong>total revenues of $43.24\u202fbillion<\/strong>, up <strong>11% year\u2011on\u2011year (YOY)<\/strong> on a constant\u2011currency basis. Product sales reached <strong>$41.03\u202fbillion<\/strong>, a <strong>9%<\/strong> increase YoY. Quarterly revenue for Q3\u201125 was <strong>$15.19\u202fbillion<\/strong>, up <strong>10%<\/strong>. The company left its full\u2011year guidance unchanged.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-financial-highlights\">Key Financial Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q3\u202f2025 (USD\u202fbn)<\/th><th>Q3\u202f2025 YoY<\/th><th>9\u2011Month 2025 (USD\u202fbn)<\/th><th>9\u2011Month YoY<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td><strong>$15.19<\/strong><\/td><td><strong>+10%<\/strong><\/td><td><strong>$43.24<\/strong><\/td><td><strong>+11%<\/strong><\/td><\/tr><tr><td><strong>Product Sales<\/strong><\/td><td>\u2014<\/td><td>\u2014<\/td><td><strong>$41.03<\/strong><\/td><td><strong>+9%<\/strong><\/td><\/tr><tr><td><strong>Adjusted EPS<\/strong><\/td><td>$2.55<\/td><td>+7%<\/td><td>$8.42<\/td><td>+6%<\/td><\/tr><tr><td><strong>Operating Margin<\/strong><\/td><td>31.2%<\/td><td>+0.8 pts<\/td><td>30.9%<\/td><td>+0.6 pts<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><em>All growth figures are presented in constant\u2011currency terms.<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-therapeutic-area-performance-9-month\">Therapeutic\u2011Area Performance (9\u2011Month)<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology<\/strong> \u2013 <strong>+16%<\/strong> YoY<\/li>\n\n\n\n<li><strong>Respiratory &amp; Immunology<\/strong> \u2013 <strong>+13%<\/strong> YoY<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-q3-2025-top-selling-products\">Q3\u202f2025 Top\u2011Selling Products<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product (Therapeutic Area)<\/th><th>Q3\u202f2025 Sales (USD\u202fbn)<\/th><th>YoY Growth<\/th><\/tr><\/thead><tbody><tr><td><strong>Tagrisso<\/strong> (osimertinib \u2013 lung cancer)<\/td><td><strong>$1.86<\/strong><\/td><td><strong>+10%<\/strong><\/td><\/tr><tr><td><strong>Imfinzi<\/strong> (durvalumab \u2013 PD\u2011L1 inhibitor)<\/td><td><strong>$1.60<\/strong><\/td><td><strong>+31%<\/strong><\/td><\/tr><tr><td><strong>Enhertu<\/strong> (trastuzumab deruxtecan \u2013 HER2 ADC)<\/td><td><strong>$0.714<\/strong><\/td><td><strong>+39%<\/strong><\/td><\/tr><tr><td><strong>Farxiga<\/strong> (dapagliflozin \u2013 diabetes)<\/td><td><strong>$2.14<\/strong><\/td><td><strong>+8%<\/strong><\/td><\/tr><tr><td><strong>Fasenra<\/strong> (benralizumab \u2013 asthma)<\/td><td><strong>$0.530<\/strong><\/td><td><strong>+20%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-geographic-breakdown\">Geographic Breakdown<\/h2>\n\n\n\n<p>AstraZeneca reported growth across all regions, with <strong>Emerging Markets (excluding China)<\/strong> delivering the strongest momentum.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Q3\u202f2025 Sales (USD\u202fmn)<\/th><th>Q3\u202f2025 YoY<\/th><th>9\u2011Month Sales (USD\u202fmn)<\/th><th>9\u2011Month YoY<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>6,548<\/td><td>+9%<\/td><td>18,517<\/td><td>+11%<\/td><\/tr><tr><td><strong>Emerging Markets ex. China<\/strong><\/td><td>2,196<\/td><td>+25%<\/td><td>6,378<\/td><td>+21%<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td>1,764<\/td><td>+5%<\/td><td>5,279<\/td><td>+5%<\/td><\/tr><tr><td><strong>Emerging Markets (total)<\/strong><\/td><td>3,960<\/td><td>+15%<\/td><td>11,657<\/td><td>+13%<\/td><\/tr><tr><td><strong>Europe<\/strong><\/td><td>3,334<\/td><td>+10%<\/td><td>9,160<\/td><td>+9%<\/td><\/tr><tr><td><strong>Established ROW<\/strong><\/td><td>1,349<\/td><td>+5%<\/td><td>3,902<\/td><td>+5%<\/td><\/tr><tr><td><strong>Total<\/strong><\/td><td>15,191<\/td><td>+10%<\/td><td>43,236<\/td><td>+11%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-outlook\">Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Full\u2011Year Guidance<\/strong> \u2013 AstraZeneca kept its 2025 revenue and earnings guidance unchanged, reaffirming expectations of <strong>mid\u2011single\u2011digit revenue growth<\/strong> and <strong>steady operating margin expansion<\/strong>.<\/li>\n\n\n\n<li><strong>Pipeline Momentum<\/strong> \u2013 Late\u2011stage trials for next\u2011generation oncology and immunology candidates are expected to launch in 2026, potentially bolstering the <strong>oncology<\/strong> and <strong>respiratory<\/strong> franchises.<\/li>\n\n\n\n<li><strong>Emerging\u2011Market Focus<\/strong> \u2013 The company plans to accelerate launch activities and price\u2011access negotiations in high\u2011growth emerging markets, targeting an additional <strong>3\u20115%<\/strong> regional revenue uplift YoY.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements regarding AstraZeneca\u2019s 2025 performance, guidance and growth initiatives. Actual results may differ due to market conditions, regulatory outcomes and other risks disclosed in the company\u2019s filings.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/9M-and-Q3-2025-results-announcement.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 9M-and-Q3-2025-results-announcement.\"><\/object><a id=\"wp-block-file--media-af250ba6-7837-4710-b62f-2e834c1d684e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/9M-and-Q3-2025-results-announcement.pdf\">9M-and-Q3-2025-results-announcement<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/9M-and-Q3-2025-results-announcement.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-af250ba6-7837-4710-b62f-2e834c1d684e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca (AZ, NASDAQ: AZN) released its third\u2011quarter and nine\u2011month 2025 financial results, showing total revenues&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46042,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[130,770,27,871],"class_list":["post-46039","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-astrazeneca","tag-az","tag-finanical-reports","tag-nasdaq-azn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca Posts 11% Y\/Y Revenue Rise to $43.24\u202fbn in First Nine\u2011Months of 2025 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca (AZ, NASDAQ: AZN) released its third\u2011quarter and nine\u2011month 2025 financial results, showing total revenues of $43.24\u202fbillion, up 11% year\u2011on\u2011year (YOY) on a constant\u2011currency basis. Product sales reached $41.03\u202fbillion, a 9% increase YoY. Quarterly revenue for Q3\u201125 was $15.19\u202fbillion, up 10%. The company left its full\u2011year guidance unchanged.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46039\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca Posts 11% Y\/Y Revenue Rise to $43.24\u202fbn in First Nine\u2011Months of 2025\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca (AZ, NASDAQ: AZN) released its third\u2011quarter and nine\u2011month 2025 financial results, showing total revenues of $43.24\u202fbillion, up 11% year\u2011on\u2011year (YOY) on a constant\u2011currency basis. Product sales reached $41.03\u202fbillion, a 9% increase YoY. Quarterly revenue for Q3\u201125 was $15.19\u202fbillion, up 10%. The company left its full\u2011year guidance unchanged.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46039\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-07T03:40:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T03:40:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0701.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46039#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46039\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca Posts 11% Y\\\/Y Revenue Rise to $43.24\u202fbn in First Nine\u2011Months of 2025\",\"datePublished\":\"2025-11-07T03:40:24+00:00\",\"dateModified\":\"2025-11-07T03:40:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46039\"},\"wordCount\":302,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46039#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0701.webp\",\"keywords\":[\"AstraZeneca\",\"AZ\",\"Finanical Reports\",\"NASDAQ: AZN\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46039#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46039\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46039\",\"name\":\"AstraZeneca Posts 11% Y\\\/Y Revenue Rise to $43.24\u202fbn in First Nine\u2011Months of 2025 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46039#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46039#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0701.webp\",\"datePublished\":\"2025-11-07T03:40:24+00:00\",\"dateModified\":\"2025-11-07T03:40:25+00:00\",\"description\":\"AstraZeneca (AZ, NASDAQ: AZN) released its third\u2011quarter and nine\u2011month 2025 financial results, showing total revenues of $43.24\u202fbillion, up 11% year\u2011on\u2011year (YOY) on a constant\u2011currency basis. Product sales reached $41.03\u202fbillion, a 9% increase YoY. Quarterly revenue for Q3\u201125 was $15.19\u202fbillion, up 10%. The company left its full\u2011year guidance unchanged.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46039#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46039\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46039#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0701.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0701.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli\u202fLilly & Novo\u202fNordisk Reach U.S. Deal to Cut Obesity\u2011Drug Prices, Unlock Medicare & Medicaid Access\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46039#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca Posts 11% Y\\\/Y Revenue Rise to $43.24\u202fbn in First Nine\u2011Months of 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca Posts 11% Y\/Y Revenue Rise to $43.24\u202fbn in First Nine\u2011Months of 2025 - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca (AZ, NASDAQ: AZN) released its third\u2011quarter and nine\u2011month 2025 financial results, showing total revenues of $43.24\u202fbillion, up 11% year\u2011on\u2011year (YOY) on a constant\u2011currency basis. Product sales reached $41.03\u202fbillion, a 9% increase YoY. Quarterly revenue for Q3\u201125 was $15.19\u202fbillion, up 10%. The company left its full\u2011year guidance unchanged.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46039","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca Posts 11% Y\/Y Revenue Rise to $43.24\u202fbn in First Nine\u2011Months of 2025","og_description":"AstraZeneca (AZ, NASDAQ: AZN) released its third\u2011quarter and nine\u2011month 2025 financial results, showing total revenues of $43.24\u202fbillion, up 11% year\u2011on\u2011year (YOY) on a constant\u2011currency basis. Product sales reached $41.03\u202fbillion, a 9% increase YoY. Quarterly revenue for Q3\u201125 was $15.19\u202fbillion, up 10%. The company left its full\u2011year guidance unchanged.","og_url":"https:\/\/flcube.com\/?p=46039","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-07T03:40:24+00:00","article_modified_time":"2025-11-07T03:40:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0701.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46039#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46039"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca Posts 11% Y\/Y Revenue Rise to $43.24\u202fbn in First Nine\u2011Months of 2025","datePublished":"2025-11-07T03:40:24+00:00","dateModified":"2025-11-07T03:40:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46039"},"wordCount":302,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46039#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0701.webp","keywords":["AstraZeneca","AZ","Finanical Reports","NASDAQ: AZN"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46039#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46039","url":"https:\/\/flcube.com\/?p=46039","name":"AstraZeneca Posts 11% Y\/Y Revenue Rise to $43.24\u202fbn in First Nine\u2011Months of 2025 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46039#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46039#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0701.webp","datePublished":"2025-11-07T03:40:24+00:00","dateModified":"2025-11-07T03:40:25+00:00","description":"AstraZeneca (AZ, NASDAQ: AZN) released its third\u2011quarter and nine\u2011month 2025 financial results, showing total revenues of $43.24\u202fbillion, up 11% year\u2011on\u2011year (YOY) on a constant\u2011currency basis. Product sales reached $41.03\u202fbillion, a 9% increase YoY. Quarterly revenue for Q3\u201125 was $15.19\u202fbillion, up 10%. The company left its full\u2011year guidance unchanged.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46039#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46039"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46039#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0701.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0701.webp","width":1080,"height":608,"caption":"Eli\u202fLilly & Novo\u202fNordisk Reach U.S. Deal to Cut Obesity\u2011Drug Prices, Unlock Medicare & Medicaid Access"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46039#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca Posts 11% Y\/Y Revenue Rise to $43.24\u202fbn in First Nine\u2011Months of 2025"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0701.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46039"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46039\/revisions"}],"predecessor-version":[{"id":46044,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46039\/revisions\/46044"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46042"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}